[The treatment of psoriasis-arthritis with cyclosporin A, a new immunosuppressive agent].
The treatment of psoriasis and psoriatic arthritis by cyclosporin A, a new immunosuppressive agent believed to have a largely selective action on T lymphocytes, is described. Results in 4 cases show that cyclosporin A can bring about a most impressive improvement in psoriatic lesions of the skin and its appendages, but that its effect on the arthropathy is variable. There is still little certainty about the compound's mechanism of action in these conditions. Cyclosporin A may give rise to a whole range of side effects and its use--like that of other immunosuppressants--should therefore be contemplated only in severe and progressive forms of psoriasis and psoriatic arthritis resistant to other forms of treatment except cytostatic drugs.
D000368:Aged; D001168:Arthritis / Q000188:drug therapy*; D003524:Cyclosporins; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*
D003524:Cyclosporins; D010456:Peptides, Cyclic
Die Behandlung der Psoriasis-Arthritis mit Cyclosporin A, einem neuen Immunsuppressivum.